Analyzing STRATA Skin Sciences (SSKN) and Its Peers

STRATA Skin Sciences (NASDAQ: SSKN) is one of 104 public companies in the “Surgical & medical instruments” industry, but how does it contrast to its rivals? We will compare STRATA Skin Sciences to similar companies based on the strength of its profitability, valuation, institutional ownership, analyst recommendations, risk, dividends and earnings.

Profitability

How to Become a New Pot Stock Millionaire

This table compares STRATA Skin Sciences and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
STRATA Skin Sciences -56.06% -38.57% -14.32%
STRATA Skin Sciences Competitors -61.96% -46.96% -18.08%

Analyst Recommendations

This is a summary of current ratings and target prices for STRATA Skin Sciences and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
STRATA Skin Sciences 0 0 2 0 3.00
STRATA Skin Sciences Competitors 494 1870 3733 112 2.56

STRATA Skin Sciences presently has a consensus target price of $9.50, indicating a potential upside of 678.69%. As a group, “Surgical & medical instruments” companies have a potential upside of 14.26%. Given STRATA Skin Sciences’ stronger consensus rating and higher probable upside, equities analysts plainly believe STRATA Skin Sciences is more favorable than its rivals.

Valuation & Earnings

This table compares STRATA Skin Sciences and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
STRATA Skin Sciences $31.45 million -$3.33 million 0.62
STRATA Skin Sciences Competitors $1.54 billion $111.91 million -139.58

STRATA Skin Sciences’ rivals have higher revenue and earnings than STRATA Skin Sciences. STRATA Skin Sciences is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

STRATA Skin Sciences has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, STRATA Skin Sciences’ rivals have a beta of 0.80, indicating that their average share price is 20% less volatile than the S&P 500.

Institutional & Insider Ownership

21.8% of STRATA Skin Sciences shares are owned by institutional investors. Comparatively, 48.3% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 12.9% of STRATA Skin Sciences shares are owned by insiders. Comparatively, 16.7% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

STRATA Skin Sciences beats its rivals on 7 of the 13 factors compared.

STRATA Skin Sciences Company Profile

STRATA Skin Sciences, Inc., a medical technology company, engages in developing and commercializing products for the treatment of dermatological disorders. Its products include XTRAC and VTRAC devices used for the treatment of psoriasis, vitiligo, and other skin disorders; and MelaFind system, an instrument for aiding dermatologists in the evaluation of clinically atypical pigmented skin lesions, when a dermatologist chooses to obtain additional information before making a final decision to biopsy in order to rule out melanoma. The company was formerly known as MELA Sciences, Inc. and changed its name to STRATA Skin Sciences, Inc. in December 2015. STRATA Skin Sciences, Inc. was founded in 1989 and is based in Horsham, Pennsylvania.

Receive News & Ratings for STRATA Skin Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STRATA Skin Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply